Publications by authors named "Chiara Zanusso"

Claim this Profile
T
Time is running out. No excuses to delay implementation of antimicrobial stewardship programmes: impact, sustainability, resilience and efficiency through an interrupted time series analysis (2017-2022).
Giovanni Del Fabro, Sergio Venturini, Manuela Avolio, Giancarlo Basaglia, Astrid Callegari, Chiara Zanusso

JAC Antimicrob Resist· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial Stewardship in the Covid-19 Pandemic.
Sergio Venturini, Manuela Avolio, Sara Fossati, Astrid Callegari, Rita De Rosa, Chiara Zanusso

Hosp Pharm· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Erika Cecchin, Elena De Mattia, Eva Dreussi, Marcella Montico, Elisa Palazzari, Chiara Zanusso

Radiother Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Sara Gagno, Elena Poletto, Michele Bartoletti, Luca Quartuccio, Chiara Romualdi, Chiara Zanusso

Gynecol Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Sara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, Chiara Zanusso, Fabio Puglisi

Clin Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
rs4143815-, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.
Chiara Zanusso, Eva Dreussi, Roberto Bortolus, Chiara Romualdi, Sara Gagno

Int J Mol Sci· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.
Elena De Mattia, Eva Dreussi, Marcella Montico, Sara Gagno, Chiara Zanusso

Front Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer.
Chiara Zanusso, Roberto Bortolus, Eva Dreussi, Jerry Polesel, Marcella Montico

Oncotarget· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
Marica Garziera, Ettore Bidoli, Erika Cecchin, Enrico Mini, Stefania Nobili, Chiara Zanusso

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Eva Dreussi, Salvatore Pucciarelli, Antonino De Paoli, Jerry Polesel, Vincenzo Canzonieri, Chiara Zanusso

Oncotarget· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis